News
Precision Antibody Expands Antibody Characterization Services
COLUMBIA, Md., March 15, 2012 —Precision Antibody, a market leader in contract antibody services, announced today that they have expanded their antibody characterization services to include Fortebio’s Octet RED96™ system, a multi-functional, label-free, real-time binding analysis instrument.
Since 2006, Precision Antibody has been providing antibody characterization services using Biacore™ 3000 by GE Healthcare, a Surface Plasmon Resonance (SPR) based real time binding kinetic analysis machine. We are now proud to announce the addition of the Octet RED96 from ForteBio to enhance our cutting edge antibody characterization capabilities and services. The Octet Red96 uses Bio-Layer Interferometry (BLI) technology for the detection of label-free real time molecular interaction analysis.
The Octet Red96 can perform up to 8 label-free binding assays at one time, allowing high throughput antibody screening and characterization. The technology is fully integrated into Precision Antibody’s custom monoclonal antibody development platform to aid the selection of suitable application-specific clones otherwise missed in a conventional EIA based screening format.
Octet Red96 can be used for the screening of monoclonal antibodies using unlabeled free antigen in solution, antibody quantification, affinity based antibody ranking, epitope binning, full binding kinetic analysis, and more. Binding kinetic analyses can be performed with molecules as small as 150 Dalton.
“We are excited to offer an additional cutting edge technology to our customers. Together with our state-of-the-art monoclonal antibody development platform technology, we continue to deliver the highest quality antibodies to our customers” says Jun Hayashi, Ph.D., the VP of Precision Antibody.
Octet RED96™ is a registered trademark of ForteBio, Inc. Precision Antibody is not affiliated with ForteBio, Inc. products or services. Biacore™ is a registered trademark of GE Healthcare. Precision Antibody is not affiliated with GE Healthcare products or services.
About Precision Antibody
Precision Antibody™ provides customized, high-affinity monoclonal and polyclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions. Precision Antibody™ develops antibodies for the use in research and discovery, for the development of preclinical therapeutic and diagnostic targets, and for QC and PK studies. The company’s products and services are based on a proprietary antibody discovery and development platform technology that enables rapid development of target-specific, high-affinity antibodies. Precision Antibody™ provides one-stop service for antibody development, characterization (isotype and affinity determination), purification/production (from pilot to large scale), and conjugation, as well as stable cell line development and hybridoma cell banking. Precision Antibody™ is a wholly owned service division of A&G Pharmaceutical, Inc. and is based in Columbia, MD.